ArticleBMC biology2025
Prediction and analysis of anti-aging peptides using data augmentation and machine learning algorithms.
Article in BMC biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Sustainable Discovery of Natural Anti-Aging Bioactives from Food Resources: Current Status and Machine Learning Perspectives.Current issues in molecular biology · 2026Review
- INBAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Advances in anti-aging Drug research leveraging multi-omics and artificial intelligence.Frontiers in aging · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundFor most species, Aging is an inevitable biological process that poses significant challenges to global healthcare due to age-related diseases. Recent advances in peptide therapy have highlighted anti-aging peptides (AAPs) as a promising therapeutic strategy, owing to their low immunogenicity and ease of synthesis. However, the lack of computational tools for AAP identification has hindered systematic research in this field.
resultsIn this study, we provided a benchmark dataset of anti-aging peptides (AAPs) based on their annotated biological functions and AgingBase database. Subsequently, we proposed three novel predictive models, including 1) Antiaging-FL, which integrates feature representation learning with machine learning algorithms; 2) ESM_GAN, which utilizes a generative adversarial network (GAN) for data augmentation to enhance prediction robustness; and 3) ESM_CNN, which combines a data augmentation strategy based on conservative amino acid substitutions with a convolutional neural network (CNN) architecture for improved feature extraction. Comprehensive evaluations demonstrated that all three models achieved high predictive performance. Specifically, Antiaging-FL achieved an AUC of 1.00 on the AAP400 dataset and 0.99 on an independent test set, while ESM_GAN yielded AUCs of 0.99 and 0.95, and ESM_CNN obtained AUCs of 0.96 and 0.94, respectively.
conclusionsOur study presents three high-performance models for AAP prediction, accelerating the discovery of novel anti-aging peptides. These models not only provide a valuable resource for researchers but also offer insights into the functional mechanisms of AAPs, paving the way for targeted drug development in aging-related therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.